Computer Vision in Healthcare
APAC · 2 shared keywords
Updated
Reviewed by Chandani Patel
APAC AI in Pathology Market Industry Trends and Forecast to 2034: Segmented by (Application, Component, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$543.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $47.8 Mn | — | — |
| 2025 (base) | $61.6 Mn | +$13.8 Mn | — |
| 2026 (forecast) | $79.5 Mn | +$17.8 Mn | +28.9% |
| 2027 (forecast) | $102.4 Mn | +$23.0 Mn | +66.2% |
| 2028 (forecast) | $132.0 Mn | +$29.6 Mn | +114.2% |
| 2029 (forecast) | $170.2 Mn | +$38.2 Mn | +176.1% |
| 2030 (forecast) | $219.4 Mn | +$49.2 Mn | +255.8% |
| 2031 (forecast) | $282.7 Mn | +$63.4 Mn | +358.7% |
| 2032 (forecast) | $364.5 Mn | +$81.7 Mn | +491.2% |
| 2033 (forecast) | $469.8 Mn | +$105.3 Mn | +662.1% |
| 2034 (forecast) | $605.6 Mn | +$135.8 Mn | +882.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $61.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $605.6 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 28.9% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Application, component and end user (see all) |
| Key players | Paige, PathAI, Ibex Medical Analytics, Philips Healthcare, Roche and 1 more (see all) |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
AI in pathology analyses digital images of tissue slides to help pathologists find cancer and other diseases faster and more consistently.
Key segments of the AI in Pathology market include application (Cancer Detection, Grading and Biomarker Scoring) and component (Software and Services).
Advances in machine learning and large language models, more digital health data, clinician shortages and pressure to cut costs are driving the AI in Pathology market. Health systems are moving from pilots to wider use.
Generative AI, automation of paperwork and AI tools approved as medical devices give the AI in Pathology market strong growth, including in emerging health systems.
Concerns about accuracy, bias, privacy and liability, along with unclear regulation and the cost of fitting AI into clinical workflows, hold back the AI in Pathology market.
The AI in Pathology market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
In some of the countries we cover here, rules for health software come from TGA (Australia)[1], NMPA (China)[2] and PMDA (Japan)[3]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[4], basic medical insurance (China)[5], the Hospital Authority (Hong Kong)[6], Ayushman Bharat PM-JAY (India)[7], public health insurance (Japan)[8], subsidised public care (Malaysia)[9], Pharmac (New Zealand)[10], PhilHealth (Philippines)[11], MediShield Life (Singapore)[12] and the Universal Coverage Scheme (Thailand)[13].
[1] Therapeutic Goods Administration. Checked 14 Nov 2026.
[2] National Medical Products Administration. Checked 14 Nov 2026.
[3] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
[4] Pharmaceutical Benefits Scheme. Checked 14 Nov 2026.
[5] National Healthcare Security Administration. Checked 14 Nov 2026.
[6] Hospital Authority. Checked 14 Nov 2026.
[7] National Health Authority (PM-JAY). Checked 14 Nov 2026.
[8] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
[9] Ministry of Health Malaysia. Checked 14 Nov 2026.
[10] Pharmac. Checked 14 Nov 2026.
[11] PhilHealth. Checked 14 Nov 2026.
[12] CPF Board, MediShield Life. Checked 14 Nov 2026.
[13] National Health Security Office. Checked 14 Nov 2026.
Rules on software as a medical device, data privacy (such as HIPAA and GDPR) and telehealth reimbursement shape the AI in Pathology market. Government digital health programs in APAC are speeding up adoption.
What doctors and scientists are doing in AI in Pathology right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
APAC · 2 shared keywords
APAC · 2 shared keywords
APAC · 1 shared keyword
APAC
APAC
APAC
Pharmaceuticals · APAC
Medical Devices · APAC
Medical Devices · APAC
Healthcare Services · APAC
Pharmaceuticals · APAC
Pharmaceuticals · APAC